Cited by 273Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisOccupational and environmental lung diseasesChronic Obstructive Pulmonary Disease (COPD) Research

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study

Open access

Maher, Toby M, Oballa, Eunice, Simpson, Juliet K, Porte, Joanne, Habgood, Anthony, Fahy, William A, Flynn, Aiden, Molyneaux, Philip L, Braybrooke, Rebecca, Divyateja, Hrushikesh, Parfrey, Helen, Rassl, Doris, Russell, Anne-Marie, Saini, Gauri, Renzoni, Elisabetta A, Duggan, Anne-Marie, Hubbard, Richard, Wells, Athol U, Lukey, Pauline T, Marshall, Richard P, Jenkins, R Gisli·2017·The Lancet Respiratory Medicine

DOI 10.1016/s2213-2600(17)30430-7

Open this paper in CoChat — free account

Abstract

Background Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal disorder with a variable disease trajectory. The aim of this study was to assess potential biomarkers to predict outcomes for people with IPF.Methods PROFILE is a large prospective longitudinal cohort of treatment-naive patients with IPF. We adopted a two-stage discovery and validation design using patients from the PROFILE cohort. For the discovery analysis, we examined 106 patients and 50 age and sex matched healthy controls from Nottingham University Hospitals NHS Trust and the Royal Brompton Hospital. We did an unbiased, multiplex immunoassay assessment of 123 biomarkers. We further investigated promising novel markers by immunohistochemical assessment of IPF lung tissue. In the validation analysis, we examined samples from 206 people with IPF from among the remaining 212 patients recruited to PROFILE Central England. We used the samples to attempt to replicate the biomarkers identified from the discovery analysis by use of independent immunoassays for each biomarker. We investigated the predictive power of the selected biomarkers to identify individuals with IPF who were at risk of progression or death. The PROFILE studies are registered on ClinicalTrials.gov, numbers NCT01134822 (PROFILE Central England) and NCT01110694 (PROFILE Royal Brompton Hospital).Findings In the discovery analysis, we identified four serum biomarkers (surfactant protein D, matrix metalloproteinase 7, CA19-9, and CA-125) that were suitable for replication. Histological assessment of CA19-9 and CA-125 suggested that these proteins were markers of epithelial damage. Replication analysis showed that baseline values of surfactant protein D (46·6 ng/mL vs 34·6 ng/mL, p=0·0018) and CA19-9 (53·7 U/mL vs 22·2 U/mL; p<0·0001) were significantly higher in patients with progressive disease than in patients with stable disease, and rising concentrations of CA-125 over 3 months were associated with increased risk of mortality (HR 2·542, 95% CI 1·493-4·328, p=0·00059).Interpretation We have identified serum proteins secreted from metaplastic epithelium that can be used to predict disease progression and death in IPF.Funding GlaxoSmithKline R&D and the UK Medical Research Council.

Integrity signals

Registry

Crossref · 10.1016/s2213-2600(17)30430-7

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
Reck, M., Kaiser, R., Mellemgaard, A., Douillard, J.-Y., Orlov, S., Krzakowski, M., von Pawel, J., Gottfried, M., Bondarenko, I., Liao, M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70586-2 · Cited by 951
Pathogenesis of Idiopathic Pulmonary Fibrosis
Wolters, P. J., Collard, H. R., & Jones, K. D. (2013) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012513-104706 · Cited by 888
Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis
Fingerlin, T. E., Murphy, E., Zhang, W., Peljto, A. L., Brown, K. K., Steele, M. P., Loyd, J. E., Cosgrove, G. P., Lynch, D., Groshong, S., et al. (2013) · Nature Genetics · doi:10.1038/ng.2609 · Cited by 809
Self-citation
MMP1 and MMP7 as Potential Peripheral Blood Biomarkers in Idiopathic Pulmonary Fibrosis
Rosas, I. O., Richards, T. J., Konishi, K., Zhang, Y., Gibson, K., Lokshin, A. E., Lindell, K. O., Cisneros, J., MacDonald, S. D., Pardo, A., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050093 · Cited by 582
Regulation of Transforming Growth Factor-β1–driven Lung Fibrosis by Galectin-3
MacKinnon, A. C., Gibbons, M., Farnworth, S. L., Leffler, H., Nilsson, U. J., Delaine, T., Simpson, A. J., Forbes, S. J., Hirani, N., Gauldie, J., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201106-0965oc · Cited by 527
The Clinical Utility of CA 19-9 in Pancreatic Adenocarcinoma: Diagnostic and Prognostic Updates
Poruk, K. E., Gay, D., Brown, K. S., Mulvihill, J. D., Boucher, K. M., Scaife, C. L., Firpo, M. A., & Mulvihill, S. J. (2013) · Current Molecular Medicine · doi:10.2174/1566524011313030003 · Cited by 396
Clinical usefulness of carbohydrate antigen 19‐9 as a screening test for pancreatic cancer in an asymptomatic population
KIM, J., Lee, K. T., Lee, J. K., Paik, S. W., Rhee, P., & Choi, K. W. (2004) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2004.03219.x · Cited by 395

Show all 34 references

Sorted by citations

Pathogenic Mechanisms Underlying Idiopathic Pulmonary Fibrosis
Moss, B. J., Ryter, S. W., & Rosas, I. O. (2021) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-042320-030240 · Cited by 852
Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation.
Leard, L. E., Holm, A. M., Valapour, M., Glanville, A. R., Attawar, S., Aversa, M., Campos, S. V., Christon, L. M., Cypel, M., Dellgren, G., et al. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.07.005 · Cited by 821
Idiopathic pulmonary fibrosis: pathogenesis and management
Sgalla, G., Iovene, B., Calvello, M., Ori, M., Varone, F., & Richeldi, L. (2018) · Respiratory Research · doi:10.1186/s12931-018-0730-2 · Cited by 573
Interstitial lung diseases
Wijsenbeek, M. S., Suzuki, A., & Maher, T. M. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01052-2 · Cited by 576
Self-citation
Idiopathic pulmonary fibrosis: state of the art for 2023
Podolanczuk, A. J., Thomson, C. C., Remy-Jardin, M., Richeldi, L., Martinez, F. J., Kolb, M., & Raghu, G. (2023) · European Respiratory Journal · doi:10.1183/13993003.00957-2022 · Cited by 359
Carbohydrate antigen 19-9 — tumor marker: Past, present, and future
Lee, T., Teng, T. Z. J., & Shelat, V. G. (2020) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v12.i12.468 · Cited by 294
The natural history of progressive fibrosing interstitial lung diseases
Kolb, M. R. J., & Vašáková, M. (2019) · Respiratory Research · doi:10.1186/s12931-019-1022-1 · Cited by 281
Therapeutic targets in lung tissue remodelling and fibrosis
Liu, G., Philp, A. M., Corte, T. J., Travis, M. A., Schilter, H. C., Hansbro, N. G., Burns, C. J., Eapen, M. S., Sohal, S. S., Burgess, J. K., et al. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107839 · Cited by 262
Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases
Kim, S., Park, B. K., Seo, J. H., Choi, J., Choi, J. W., Lee, C. K., Chung, J. B., Park, Y., & Kim, D. W. (2020) · Scientific Reports · doi:10.1038/s41598-020-65720-8 · Cited by 193
Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis
Kreuter, M., Lee, J. S., Tzouvelekis, A., Oldham, J. M., Molyneaux, P. L., Weycker, D. A., Atwood, M., Kirchgaessler, K.-U., & Maher, T. M. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202003-0669oc · Cited by 191
Self-citation
Common Pathogenic Mechanisms Between Idiopathic Pulmonary Fibrosis and Lung Cancer
Τzouvelekis, Α., Gomatou, G., Bouros, E., Trigidou, R., Tzilas, V., & Bouros, D. E. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.04.114 · Cited by 182
Precision medicine advances in idiopathic pulmonary fibrosis
Karampitsakos, Τ., Juan-Guardela, B. M., Τzouvelekis, Α., & Herazo‐Maya, J. D. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104766 · Cited by 148
A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis
Lukey, P. T., Harrison, S. A., Yang, S., Man, Y., Holman, B. F., Rashidnasab, A., Azzopardi, G., Grayer, M., Simpson, J. K., Bareille, P. J., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01992-2018 · Cited by 150
Self-citation
Biomarkers of collagen synthesis predict progression in the PROFILE idiopathic pulmonary fibrosis cohort
Organ, L. A., Duggan, A.-M. R., Oballa, E., Taggart, S. C., Simpson, J. K., Kang’ombe, A. R., Braybrooke, R., Molyneaux, P. L., North, B., Karkera, Y., et al. (2019) · Respiratory Research · doi:10.1186/s12931-019-1118-7 · Cited by 139
Self-citation
Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype
Inoue, Y., Kaner, R. J., Guiot, J., Maher, T. M., Tomassetti, S., Moiseev, S., Kuwana, M., & Brown, K. K. (2020) · Chest · doi:10.1016/j.chest.2020.03.037 · Cited by 133
Self-citation
Biomarkers in idiopathic pulmonary fibrosis
Drakopanagiotakis, F., Wujak, L., Wygrecka, M., & Markart, P. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.01.023 · Cited by 132
Advances in the management of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis
Liu, G. Y., Budinger, G. R. S., & Dematte, J. E. (2022) · BMJ · doi:10.1136/bmj-2021-066354 · Cited by 125
Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials
Neighbors, M., Cabanski, C. R., Ramalingam, T. R., Sheng, X. R., Tew, G. W., Gu, C., Jia, G., Peng, K., Ray, J., Ley, B., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30185-1 · Cited by 117
Treatment of fibrotic interstitial lung disease: current approaches and future directions
Johannson, K. A., Chaudhuri, N., Adegunsoye, A., & Wolters, P. J. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01826-2 · Cited by 116
Fibrosis: cross-organ biology and pathways to development of innovative drugs
Rieder, F., Nagy, L. E., Maher, T. M., Distler, J. H. W., Kramann, R., Hinz, B., & Prunotto, M. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01158-9 · Cited by 134
Self-citation
Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study
Maher, T. M., Stowasser, S., Nishioka, Y., White, E. S., Cottin, V., Noth, I., Selman, M., Rohr, K. B., Michael, A., Ittrich, C., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30255-3 · Cited by 107
Self-citation
Integrated Single Cell Analysis of Human Lung Fibrosis Resolves Cellular Origins of Predictive Protein Signatures in Body Fluids
Mayr, C. H., Simon, L. M., Leuschner, G., Ansari, M., Gote-Schniering, J., Geyer, P. E., Angelidis, I., Strunz, M., Singh, P., Kneidinger, N., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012871 · Cited by 109
Beyond epithelial damage: vascular and endothelial contributions to idiopathic pulmonary fibrosis
May, J. M., Mitchell, J. A., & Jenkins, G. R. (2023) · Journal of Clinical Investigation · doi:10.1172/jci172058 · Cited by 110
Idiopathic Pulmonary Fibrosis: Best Practice in Monitoring and Managing a Relentless Fibrotic Disease
Wuyts, W. A., Wijsenbeek, M. S., Bondue, B., Bouros, D. E., Bresser, P., Cordeiro, C. R., Hilberg, O., Magnusson, J. M., Manali, E. D., Morais, A., et al. (2019) · Respiration · doi:10.1159/000504763 · Cited by 96
Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on ‘Feels, Functions, Survives’. Report of a Collaborative Discussion in a Symposium with Direct Engagement from Representatives of Patients, Investigators, the National Institutes of Health, a Patient Advocacy Organization, and a Regulatory Agency
Raghu, G., Ghazipura, M., Fleming, T. R., Aronson, K. I., Behr, J., Brown, K. M., Flaherty, K. R., Kazerooni, E. A., Maher, T. M., Richeldi, L., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202312-2213so · Cited by 108
Self-citation
Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry
on behalf of the IPF-PRO Registry investigators, Todd, J. L., Neely, M. L., Overton, R. A., Durham, K., Gulati, M., Huang, H. J., Roman, J., Newby, L. K., Flaherty, K. R., et al. (2019) · Respiratory Research · doi:10.1186/s12931-019-1190-z · Cited by 93
Biomarker signatures for progressive idiopathic pulmonary fibrosis
Clynick, B., Corte, T. J., Jo, H. E., Stewart, I., Glaspole, I. N., Grainge, C., Maher, T. M., Navaratnam, V., Hubbard, R., Hopkins, P. M. A., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.01181-2021 · Cited by 86
Self-citation
The Many Faces of Matrix Metalloproteinase-7 in Kidney Diseases
Liu, Z., Tan, R. J., & Liu, Y. (2020) · Biomolecules · doi:10.3390/biom10060960 · Cited by 86
Circulating Plasma Biomarkers of Survival in Antifibrotic-Treated Patients With Idiopathic Pulmonary Fibrosis
Adegunsoye, A., Alqalyoobi, S., Linderholm, A., Bowman, W. S., Lee, C. T., Pugashetti, J. V., Sarma, N., Ma, S.-F., Haczku, A., Sperling, A., et al. (2020) · Chest · doi:10.1016/j.chest.2020.04.066 · Cited by 82
Imaging research in fibrotic lung disease; applying deep learning to unsolved problems
Walsh, S. L. F., Humphries, S. M., Wells, A. U., & Brown, K. K. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30003-5 · Cited by 82
Self-citation
Biomarkers in Progressive Fibrosing Interstitial Lung Disease: Optimizing Diagnosis, Prognosis, and Treatment Response
Bowman, W. S., Echt, G., & Oldham, J. M. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.680997 · Cited by 81
Molecular Biomarkers in Idiopathic Pulmonary Fibrosis: State of the Art and Future Directions
Stainer, A., Faverio, P., Busnelli, S., Catalano, M., Zoppa, M. D., Marruchella, A., Pesci, A., & Luppi, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126255 · Cited by 80
Proteomic Biomarkers of Survival in Idiopathic Pulmonary Fibrosis
Oldham, J. M., Huang, Y., Bose, S., Ma, S.-F., Kim, J. S., Schwab, A., Ting, C., Mou, K., Lee, C. T., Adegunsoye, A., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202301-0117oc · Cited by 72
Circulating lung biomarkers in idiopathic lung fibrosis and interstitial lung diseases associated with connective tissue diseases: Where do we stand?
Elhaï, M., Avouac, J., & Allanore, Y. (2020) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2020.01.006 · Cited by 73
Serum KL-6, CA19-9, CA125 and CEA are Diagnostic Biomarkers for Rheumatoid Arthritis-Associated Interstitial Lung Disease in the Chinese Population
Zheng, M., Lou, A., Zhang, H., Zhu, S., Yang, M., & Lai, W. (2021) · Rheumatology and Therapy · doi:10.1007/s40744-021-00288-x · Cited by 70
Two sides of the same coin? A review of the similarities and differences between idiopathic pulmonary fibrosis and rheumatoid arthritis-associated interstitial lung disease
Matson, S. M., Lee, J. S., & Eickelberg, O. (2020) · European Respiratory Journal · doi:10.1183/13993003.02533-2020 · Cited by 71
Increased monocyte count and red cell distribution width as prognostic biomarkers in patients with Idiopathic Pulmonary Fibrosis
Karampitsakos, Τ., Torrisi, S. E., Antoniou, K. M., Manali, E. D., Korbila, I. P., Παπαϊωάννου, Ο., Sampsonas, F., Katsaras, M., Vasarmidi, E., Papakosta, D., et al. (2021) · Respiratory Research · doi:10.1186/s12931-021-01725-9 · Cited by 71
Targeting Alveolar Repair in Idiopathic Pulmonary Fibrosis
Ptasinski, V., Stegmayr, J., Belvisi, M. G., Wagner, D. E., & Murray, L. A. (2021) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0476tr · Cited by 60
Gene correlation network analysis to identify regulatory factors in idiopathic pulmonary fibrosis
McDonough, J. E., Kaminski, N., Thienpont, B., Hogg, J. C., Vanaudenaerde, B. M., & Wuyts, W. A. (2018) · Thorax · doi:10.1136/thoraxjnl-2018-211929 · Cited by 58
A systematic review of blood biomarkers with individual participant data meta-analysis of matrix metalloproteinase-7 in idiopathic pulmonary fibrosis
Khan, F., Stewart, I. D., Saini, G., Robinson, K. A., & Jenkins, G. R. (2021) · European Respiratory Journal · doi:10.1183/13993003.01612-2021 · Cited by 60
Self-citation
Challenges for Clinical Drug Development in Pulmonary Fibrosis
White, E. S., Thomas, M. J., Stowasser, S., & Tetzlaff, K. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.823085 · Cited by 62
Cell Cross-Talk in Alveolar Microenvironment: From Lung Injury to Fibrosis
Song, L., Li, K., Chen, H., & Xie, L. (2024) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2023-0426tr · Cited by 64
Pulmonary fibrosis: Emerging diagnostic and therapeutic strategies
Selvarajah, B., Platé, M., & Chambers, R. C. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101227 · Cited by 57
Mucins as a New Frontier in Pulmonary Fibrosis
Ballester, B., Milara, J., & Cortijo, J. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8091447 · Cited by 59
Pulmonary alveolar microlithiasis
Kosciuk, P., Meyer, C. A., Wikenheiser‐Brokamp, K. A., & McCormack, F. X. (2020) · European Respiratory Review · doi:10.1183/16000617.0024-2020 · Cited by 55
The Epithelial-Immune Crosstalk in Pulmonary Fibrosis
Planté-Bordeneuve, T., Pilette, C., & Froidure, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.631235 · Cited by 59
Circulating Plasma Biomarkers of Progressive Interstitial Lung Disease
Alqalyoobi, S., Adegunsoye, A., Linderholm, A., Hrusch, C. L., Cutting, C. C., Ma, S., Sperling, A. I., Noth, I., Strek, M. E., & Oldham, J. M. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201907-1343le · Cited by 53
CYFRA 21-1 Predicts Progression in Idiopathic Pulmonary Fibrosis: A Prospective Longitudinal Analysis of the PROFILE Cohort
Molyneaux, P. L., Fahy, W. A., Byrne, A. J., Braybrooke, R., Saunders, P. T., Toshner, R., Albers, G. J., Chua, F., Renzoni, E. A., Wells, A. U., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202107-1769oc · Cited by 52
Self-citation
Analysis of the Interaction Network of Hub miRNAs-Hub Genes, Being Involved in Idiopathic Pulmonary Fibers and Its Emerging Role in Non-small Cell Lung Cancer
Yu, D. H., Ruan, X., Huang, J., Liu, X., Ma, H., Chen, C., Hu, W., & Li, S. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00302 · Cited by 51
Identifying potential biomarkers of idiopathic pulmonary fibrosis through machine learning analysis
Wu, Z., Chen, H., Ke, S., Mo, L., Qiu, M., Zhu, G., Zhu, W., & Liu, L. (2023) · Scientific Reports · doi:10.1038/s41598-023-43834-z · Cited by 53
Sustained amphiregulin expression in intermediate alveolar stem cells drives progressive fibrosis
Zhao, R., Wang, Z., Wang, G., Geng, J., Wu, H., Liu, X., Bin, E., Sui, J., Dai, H., & Tang, N. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.07.004 · Cited by 52
Significance of molecular biomarkers in idiopathic pulmonary fibrosis: A mini review
Chiba, H., Otsuka, M., & Takahashi, H. (2018) · Respiratory Investigation · doi:10.1016/j.resinv.2018.06.001 · Cited by 50
Recapitulating idiopathic pulmonary fibrosis related alveolar epithelial dysfunction in a human iPSC‐derived air‐liquid interface model
Schruf, E., Schroeder, V., Le, H. Q., Schönberger, T., Raedel, D., Stewart, E. L., Fundel‐Clemens, K., Bluhmki, T., Weigle, S., Schuler, M. J., et al. (2020) · The FASEB Journal · doi:10.1096/fj.201902926r · Cited by 50
Blood Transcriptomics Predicts Progression of Pulmonary Fibrosis and Associated Natural Killer Cells
Huang, Y., Oldham, J. M., Ma, S., Unterman, A., Liao, S.-Y., Barros, A. J., Bonham, C. A., Kim, J. S., Vij, R., Adegunsoye, A., et al. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202008-3093oc · Cited by 48
Self-citation
Serial Measurements of Circulating KL-6, SP-D, MMP-7, CA19-9, CA-125, CCL18, and Periostin in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Therapy: An Exploratory Study
Majewski, S., Szewczyk, K., Żal, A., Białas, A. J., Miłkowska-Dymanowska, J., & Piotrowski, W. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10173864 · Cited by 46
Prognostic factors in chronic hypersensitivity pneumonitis
Creamer, A. W., & Barratt, S. L. (2020) · European Respiratory Review · doi:10.1183/16000617.0167-2019 · Cited by 44
Risk factors associated with the development of interstitial lung abnormalities
Buendía-Roldán, I., Fernández, R., Mejía, M. E., Juárez-Hernández, F., Ramírez-Martínez, G., Montes, E., Pruneda, A. K. S., Martínez‐Espinosa, K., Alarcón-Dionet, A., Herrera, I., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.03005-2020 · Cited by 41
The role of precision medicine in interstitial lung disease
Maher, T. M., Nambiar, A. M., & Wells, A. U. (2022) · European Respiratory Journal · doi:10.1183/13993003.02146-2021 · Cited by 38
Self-citation
Management of Connective Tissue Disease–related Interstitial Lung Disease
Ahmed, S., & Handa, R. (2022) · Current Pulmonology Reports · doi:10.1007/s13665-022-00290-w · Cited by 38
Existing and emerging biomarkers for disease progression in idiopathic pulmonary fibrosis
Inchingolo, R., Varone, F., Sgalla, G., & Richeldi, L. (2018) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1553620 · Cited by 37
Serum amyloid A in patients with idiopathic pulmonary fibrosis
Vietri, L., Bennett, D., Cameli, P., Bergantini, L., Cillis, G., Sestini, P., Bargagli, E., & Rottoli, P. (2019) · Respiratory Investigation · doi:10.1016/j.resinv.2019.03.010 · Cited by 37
Chronic lung diseases: prospects for regeneration and repair
Barnes, P. J., Anderson, G. P., Fagerås, M., & Belvisi, M. G. (2021) · European Respiratory Review · doi:10.1183/16000617.0213-2020 · Cited by 35
Roles of biomarkers in anti‐MDA5 ‐positive dermatomyositis, associated interstitial lung disease, and rapidly progressive interstitial lung disease
Li, X., Liu, Y., Cheng, L., Huang, Y., Yan, S., Li, H., Zhan, H., & Li, Y. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24726 · Cited by 36
Integrative multi-omics analysis reveals novel idiopathic pulmonary fibrosis endotypes associated with disease progression
Ruan, P., Todd, J. L., Zhao, H., Liu, Y., Vinisko, R., Söllner, J. F., Schmid, R., Kaner, R. J., Luckhardt, T., Neely, M. L., et al. (2023) · Respiratory Research · doi:10.1186/s12931-023-02435-0 · Cited by 43
Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan
Pirfenidone Clinical Study Group in Japan, Ikeda, K., Chiba, H., Nishikiori, H., Azuma, A., Kondoh, Y., Ogura, T., Taguchi, Y., Ebina, M., Sakaguchi, H., et al. (2020) · Respiratory Research · doi:10.1186/s12931-020-01582-y · Cited by 36
Breath biomarkers in idiopathic pulmonary fibrosis: a systematic review
Hayton, C., Terrington, D. L., Wilson, A. M., Chaudhuri, N., Leonard, C. T., & Fowler, S. J. (2019) · Respiratory Research · doi:10.1186/s12931-019-0971-8 · Cited by 36
Alveolar concentration of nitric oxide as a prognostic biomarker in idiopathic pulmonary fibrosis
Cameli, P., Bergantini, L., Salvini, M., Refini, R. M., Pieroni, M., Bargagli, E., & Sestini, P. (2019) · Nitric Oxide · doi:10.1016/j.niox.2019.05.001 · Cited by 35
Cluster analysis of blood biomarkers to identify molecular patterns in pulmonary fibrosis: assessment of a multicentre, prospective, observational cohort with independent validation
Fainberg, H. P., Moodley, Y. P., Triguero, I., Corte, T. J., Sand, J. M. B., Leeming, D. J., Karsdal, M. A., Wells, A. U., Renzoni, E. A., Mackintosh, J. A., et al. (2024) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(24)00147-4 · Cited by 39
Self-citation
Serum decorin is a potential prognostic biomarker in patients with acute exacerbation of idiopathic pulmonary fibrosis
Nikaido, T., Tanino, Y., Wang, X., Sato, Y., Togawa, R., Kikuchi, M., Misa, K., Saito, K., Fukuhara, N., Kawamata, T., et al. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.08.60 · Cited by 35
Changes in Neutrophil–Lymphocyte or Platelet–Lymphocyte Ratios and Their Associations with Clinical Outcomes in Idiopathic Pulmonary Fibrosis
Nathan, S. D., Mehta, J., Stauffer, J. L., Morgenthien, E. A., Yang, M., Limb, S. L., & Bhorade, S. M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10071427 · Cited by 33
Mammalian Neuraminidases in Immune-Mediated Diseases: Mucins and Beyond
Lillehoj, E. P., Luzina, I. G., & Atamas, S. P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.883079 · Cited by 35
Serum CA125 levels are decreased in rectal cancer but increased in fibrosis-associated diseases and in most types of cancers
Zhang, M., Zhang, Y., Fu, J., & Zhang, L. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2018.12.012 · Cited by 32
MUC16: clinical targets with great potential
Zhang, X.-Y., Hong, L., & Ling, Z. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01365-5 · Cited by 33
The Dawn of Precision Medicine in Fibrotic Interstitial Lung Disease
Karampitsakos, Τ., Tourki, B., & Herazo‐Maya, J. D. (2024) · CHEST Journal · doi:10.1016/j.chest.2024.10.042 · Cited by 31
Multi-center evaluation of baseline neutrophil-to-lymphocyte (NLR) ratio as an independent predictor of mortality and clinical risk stratifier in idiopathic pulmonary fibrosis
Mikolasch, T., George, P. M., Sahota, J., Nancarrow, T., Barratt, S. L., Woodhead, F., Kouranos, V., Cope, V. S. A., Creamer, A. W., Fidan, S., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101758 · Cited by 30
Self-citation
The association between white blood cell count and outcomes in patients with idiopathic pulmonary fibrosis
Nathan, S. D., Brown, A. W., Moğulkoç, N., Soares, F. D. S. N., Collins, A., Cheng, J. M., Peterson, J., Cannon, B., King, C. S., & Barnett, S. D. (2020) · Respiratory Medicine · doi:10.1016/j.rmed.2020.106068 · Cited by 28
Genetic Variation in CCL18 Gene Influences CCL18 Expression and Correlates with Survival in Idiopathic Pulmonary Fibrosis: Part A
Wiertz, I. A., Moll, S. A., Seeliger, B., Barlo, N. P., van der Vis, J. J., Korthagen, N. M., Rijkers, G. T., Ruven, H. J. T., Grutters, J. C., Prasse, A., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061940 · Cited by 29
Genetic Variation in CCL18 Gene Influences CCL18 Expression and Correlates with Survival in Idiopathic Pulmonary Fibrosis—Part B
Caliskan, C., Seeliger, B., Jäger, B., Fuge, J., Welte, T., Terwolbeck, O., Freise, J., van Moorsel, C. H. M., Zhang, Y., & Prasse, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061993 · Cited by 28
Predictive biomarkers of disease progression in idiopathic pulmonary fibrosis
Zhu, W., Liu, C., Tan, C., & Zhang, J. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e23543 · Cited by 29
Big data-driven precision medicine: Starting the custom-made era of iatrology
Song, C. M., Kong, Y., Huang, L., Luo, H., & Zhu, X. M. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110445 · Cited by 27
BAL Is Safe and Well Tolerated in Individuals with Idiopathic Pulmonary Fibrosis: An Analysis of the PROFILE Study
Molyneaux, P. L., Smith, J. J., Saunders, P. T., Chua, F., Wells, A. U., Renzoni, E. A., Nicholson, A. G., Fahy, W. A., Jenkins, G. R., & Maher, T. M. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202004-1138le · Cited by 28
Self-citation
MUC16 Is Overexpressed in Idiopathic Pulmonary Fibrosis and Induces Fibrotic Responses Mediated by Transforming Growth Factor-β1 Canonical Pathway
Ballester, B., Milara, J., Montero, P., & Cortijo, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126502 · Cited by 25
Tumor markers are associated with rapidly progressive interstitial lung disease in adult-dermatomyositis
Wang, Q., Gao, C., Zhang, C., Yao, M., Liang, W., Sun, W., & Zheng, Z. (2022) · Clinical Rheumatology · doi:10.1007/s10067-022-06089-z · Cited by 25
A Composite Serum Biomarker Index for the Diagnosis of Systemic Sclerosis–Associated Interstitial Lung Disease: A Multicenter, Observational Cohort Study
Jee, A. S., Stewart, I. D., Youssef, P. P., Adelstein, S., Lai, D., Hua, S., Stevens, W., Proudman, S., Ngian, G., Glaspole, I., et al. (2023) · Arthritis & Rheumatology · doi:10.1002/art.42491 · Cited by 29
Pharmacological management of Idiopathic Pulmonary Fibrosis: current and emerging options
Trachalaki, A., Irfan, M., & Wells, A. U. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1822326 · Cited by 25
Self-citation
Adaptive multi-interventional trial platform to improve patient care for fibrotic interstitial lung diseases
Kawano-Dourado, L. B., Kulkarni, T., Ryerson, C. J., Rivera‐Ortega, P., Baldi, B. G., Chaudhuri, N., Funke-Chambour, M., Hoffmann‐Vold, A., Johannson, K. A., Khor, Y. H., et al. (2024) · Thorax · doi:10.1136/thorax-2023-221148 · Cited by 27
An overview of biomedical applications for gold nanoparticles against lung cancer
Kumari, V., Vishwas, S., Kumar, R., Kakoty, V., Khursheed, R., Babu, M. R., Harish, V., Mittal, N., Singh, P. K., Alharthi, N. S., et al. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104729 · Cited by 26
Systematic Review and Metanalysis of Oncomarkers in IPF Patients and Serial Changes of Oncomarkers in a Prospective Italian Real-Life Case Series
d’Alessandro, M., Bergantini, L., Torricelli, E., Cameli, P., Lavorini, F., Pieroni, M., Refini, R. M., Sestini, P., & Bargagli, E. (2021) · Cancers · doi:10.3390/cancers13030539 · Cited by 22
Genetically increased circulating FUT3 level leads to reduced risk of idiopathic pulmonary fibrosis: a Mendelian randomisation study
Nakanishi, T., Cerani, A., Forgetta, V., Zhou, S., Allen, R. J., Leavy, O. C., Koido, M., Assayag, D., Jenkins, G. R., Wain, L. V., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.03979-2020 · Cited by 22
The significance of elevated tumor markers among patients with interstitial lung diseases
Kwon, B. S., Kim, E. S., Lim, S. Y., Song, M. J., Kim, Y. W., Kim, H., Lee, Y. J., Park, J. S., Cho, Y., Yoon, H. I., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-20683-w · Cited by 22
Acute Exacerbations of Interstitial Lung Diseases: Focus on Biomarkers
Drakopanagiotakis, F., Markart, P., & Steiropoulos, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210196 · Cited by 21
αvβ6-Targeted Molecular PET/CT Imaging of the Lungs After SARS-CoV-2 Infection
Foster, C. C., Davis, R. A., Hausner, S. H., & Sutcliffe-Goulden, J. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.255364 · Cited by 20
Review: Serum Biomarkers of Lung Fibrosis in Interstitial Pneumonia with Autoimmune Features—What Do We Already Know?
Miądlikowska, E., Rzepka-Wrona, P., Miłkowska-Dymanowska, J., Białas, A. J., & Piotrowski, W. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm11010079 · Cited by 22
Potential biomarkers for diagnosis and disease evaluation of idiopathic pulmonary fibrosis
Wang, Q., Xie, Z., Wan, N., Yang, L., Jin, Z., Jin, F., Huang, Z., Chen, M., Wang, H., & Feng, J. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002171 · Cited by 20
Associations of ω-3 Fatty Acids With Interstitial Lung Disease and Lung Imaging Abnormalities Among Adults
Kim, J. S., Steffen, B. T., Podolanczuk, A. J., Kawut, S. M., Noth, I., Raghu, G., Michos, E. D., Hoffman, E. A., Axelsson, G. T., Guðmundsson, G., et al. (2020) · American Journal of Epidemiology · doi:10.1093/aje/kwaa168 · Cited by 17
Recent advances in the non-invasive assessment of fibrosis using biomarkers
Tatler, A. L. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.09.010 · Cited by 18
Idiopathic Pulmonary Fibrosis: Where do We Stand and How Far to Go?
Singh, V., Ulasov, I., Gupta, S., Singh, A., Roy, V. K., & Kharwar, R. K. (2024) · Discovery Medicine · doi:10.24976/discov.med.202436180.3 · Cited by 17
Investigating the effects of nintedanib on biomarkers of extracellular matrix turnover in patients with IPF: design of the randomised placebo-controlled INMARK®trial
Maher, T. M., Stowasser, S., Nishioka, Y., White, E. S., Cottin, V., Noth, I., Selman, M., Blahova, Z., Wachtlin, D., Diefenbach, C., et al. (2018) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2018-000325 · Cited by 17
Self-citation
Biomarkers for respiratory diseases: Present applications and future discoveries
Liu, X., Cui, B., Wang, Q., Ma, Y., Li, L., & Chen, Z. H. (2021) · Clinical and Translational Discovery · doi:10.1002/ctd2.11 · Cited by 17
Integrative analysis of lung molecular signatures reveals key drivers of idiopathic pulmonary fibrosis
Kim, S. K., Jung, S. M., Park, K., & Kim, K. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01749-3 · Cited by 17

Authors: Maher, T. M., Oballa, E., Simpson, J. K., Porte, J., Habgood, A., Fahy, W. A., Flynn, A., Molyneaux, P. L., Braybrooke, R., Divyateja, H., Parfrey, H., Rassl, D., Russell, A.-M., Saini, G., Renzoni, E. A., Duggan, A.-M., Hubbard, R., Wells, A. U., Lukey, P. T., Marshall, R. P., & Jenkins, R. G.
Affiliations: National Institute for Health and Care Research (GB)
GlaxoSmithKline (United Kingdom) (GB)
Nottingham University Hospitals NHS Trust (GB)
University of Nottingham (GB)
Royal Papworth Hospital (GB)
ORCID: Maher, Toby M
Porte, Joanne
Habgood, Anthony
Fahy, William A
Molyneaux, Philip L
Braybrooke, Rebecca
Parfrey, Helen
Rassl, Doris
Russell, Anne-Marie
Saini, Gauri
Renzoni, Elisabetta A
Hubbard, Richard
Wells, Athol U
Lukey, Pauline T
Marshall, Richard P
Venue: The Lancet Respiratory Medicine
Publisher: Elsevier BV
Published: 2017-12
Volume: 5
Issue: 12
Pages: 946-955
ISSN: 2213-2600 (ISSN-L)
DOI: 10.1016/s2213-2600(17)30430-7
OpenAlex: W2770778260
Cited by: 271
References: 34
Citations by year: 2026: 21 · 2025: 28 · 2024: 39 · 2023: 37 · 2022: 33 · 2021: 36 · 2020: 36 · 2019: 26 · 2018: 14 · 2017: 1
FWCI: 17.28
Type: journal article
Language: en
Open access: green
doi.org
Licence: other-oa
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet Respiratory Medicine (publishedVersion)
PubMed (publishedVersion)
Repository@Nottingham (University of Nottingham) (acceptedVersion, other-oa)
Repository@Nottingham (University of Nottingham) (submittedVersion, cc-by)
Nottingham ePrints (University of Nottingham) (submittedVersion, cc-by)
University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
Spiral (Imperial College London) (submittedVersion, cc-by-nc-nd)
Funders: National Institute for Health and Care Research (PB-PG-0712-28073, CS-2013-13-017, CDRF-2012-03-053)
Versus Arthritis (20719)
Medical Research Council (MR/N005953/1)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
Keywords: idiopathic pulmonary fibrosis, serum biomarkers, surfactant protein D, CA19-9, CA125, matrix metalloproteinase-7, disease progression prediction, mortality risk, epithelial damage, multiplex immunoassay, treatment-naive patients, lung histology, metaplastic epithelium, biomarker discovery
MeSH terms: Enzyme-Linked Immunosorbent Assay, Epithelium, Female, Humans, Longitudinal Studies, Lung, Male, Predictive Value of Tests, Prospective Studies, Biomarkers, Case-Control Studies, CA-125 Antigen, CA-19-9 Antigen, Disease Progression, Matrix Metalloproteinase 7, Pulmonary Surfactant-Associated Protein D, Idiopathic Pulmonary Fibrosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks